免疫介导炎症性疾病组织不可知药物试验的结局选择:核心结局集与监管指南的系统综述
该综述检索COMET、ICHOM、FDA和EMA数据库(建库至2019年12月28日),纳入44篇核心结局集(COS)出版物,映射11种免疫介导炎症性疾病(IMID)的推荐结局,并比较FDA与EMA的监管推荐。疾病活动度、疼痛、疲劳、生活质量等结局在多数疾病中被推荐;FDA与EMA推荐存在显著异同,仅青少年系统性红斑狼疮(jSLE)被两个监管机构直接引用PRINTO COS。作者认为需加强监管机构与COS开发者合作。
要点
- 44篇COS出版物覆盖11种IMID,疾病活动度、疼痛、疲劳、生活质量等为多数疾病推荐结局。
- FDA与EMA推荐存在显著异同,仅jSLE被两者共同直接引用PRINTO COS。
- 作者认为需将监管机构纳入COS开发关键利益相关方以提高COS质量。
核心结论
- 该系统综述为IMID组织不可知试验的结局选择提供有价值信息,需加强监管机构与COS开发者合作并将监管机构纳入COS开发关键利益相关方以提高COS质量。
研究设计与样本
- 系统综述,检索COMET、ICHOM、FDA和EMA数据库,检索时间自建库至2019年12月28日。
- 两名评价者独立筛选标题和摘要并进行全文筛选,手工检索参考文献列表并对入选出版物进行引文检索。
- 纳入文章的文献方法学质量依据COS-STAD清单条目独立评估,最终分析纳入44篇COS出版物。
主要发现
- 疾病活动度、疼痛、疲劳、生活质量、躯体功能、工作受限/生产力、激素使用和生物标志物等结局在多数疾病中被推荐。
- FDA与EMA的推荐存在显著相似与差异,唯一被任一监管机构直接引用COS的情况是jSLE,两者均引用PRINTO COS。
关键数值与推荐
- 最终分析纳入44篇COS出版物,覆盖11种IMID。
- 唯一被FDA或EMA直接引用COS的情况为jSLE,两者均引用PRINTO COS。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tissue-agnostic drug development provides a paradigm shift in precision medicine and requires innovative trial designs. However, outcome selection for such trials can prove challenging. The objectives of this review were to: (i) Identify and map core outcome sets (COS), across 11 immune-mediated inflammatory diseases (IMIDs) in order to facilitate the selection of relevant outcomes across the conditions for innovative trials of tissue-agnostic drug therapies. (ii) Compare outcomes or endpoints recommended by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to identify and highlight similarities and differences. METHODS: The Core Outcome Measures in Effectiveness Trials (COMET), International Consortium for Health Outcomes Measurement (ICHOM), FDA and EMA databases were searched from inception to 28th December 2019. Two reviewers independently screened titles and abstracts of retrieved entries and conducted the subsequent full text screening. Hand searching of the reference lists and citation searching of the selected publications was conducted. The methodological quality of the included peer-reviewed articles was independently assessed by the reviewers based on the items of the COS-Standards for Development recommendations (COS-STAD) checklist. Core outcomes from the included publications were extracted and mapped across studies and conditions. Regulatory guidance from FDA and EMA, where available for clinical trials for the IMIDs, were obtained from their databases and recommendations on outcomes to measure directly compared. RESULTS: Forty-four COS publications were included in the final analysis. Outcomes such as disease activity, pain, fatigue, quality of life, physical function, work limitation/productivity, steroid use and biomarkers were recommended across majority of the conditions. There were significant similarities and differences in FDA and EMA recommendations. The only instance where either regulatory body directly referenced a COS was for jSLE-both referenced the Paediatric Rheumatology International Trials Organization (PRINTO) COS. CONCLUSIONS: The findings from this systematic review provide valuable information to inform outcome selection in tissue-agnostic trials for IMIDs. There is a need for increased collaboration between regulators and COS developers and inclusion of regulators as key stakeholders in COS development to enhance the quality of COS. TRIAL REGISTRATION: Not registered.
引用
- Aiyegbusi OL, di Ruffano LF, Retzer A, et al. Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance. Trials. 2022. PMID: 35033186. doi:10.1186/s13063-022-06000-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。